MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jamacardio.2026.2510

Медицинская библиотека · JAMA cardiology · 2026

Digitally Enabled Quality Improvement Intervention and LDL-C Control in Atherosclerotic Cardiovascular Disease: The SAPPHIRE-LDL Cluster Randomized Clinical Trial.

Machline-Carrion M Julia, Santo Karla, Girotto Alysson Nathan, Raupp Priscila, Pereira Pedro Marton, Monfardini Frederico, Nakagawa Santos Renato Hideo, Pereira Mariane, Dos Santos Sampaio Bruna, Moia Diogo, de Oliveira Farias Gabriela, Dall'Orto Frederico Toledo Campo, Pavanello Ricardo, Polanczyk Carisi Anne, Silvestre Odilson Marcos, Assad Marcelo Heitor Vieira, de Oliveira Paiva Maria Sanali Moura, Dos Santos Mayler Olombrada Nunes, Okoshi Marina Politi, Bosso Carlos Eduardo da Costa Nunes, de Azeredo Bastos Leandro Andrade, de Moura Joaquim Rodrigo, Arruda José Airton, Araujo Gustavo Ferreira, Riquena Barbara, Rezende Vania, Alvarenga Lenio, Ray Kausik, Cannon Christopher P, Santos Raul D, Berwanger Otávio, SAPPHIRE-LDL Investigators

СтатьяРандомизированное исследованиеPragmatic Clinical TrialМногоцентровое исследованиеПеревод в очереди

Аннотация

IMPORTANCE

Bridging the low-density lipoprotein cholesterol (LDL-C) care gap in patients with established atherosclerotic cardiovascular disease (ASCVD) is challenging. Few quality improvement (QI) interventions have successfully improved patient care.

OBJECTIVE

To evaluate the impact of a digitally enabled, multifaceted, QI intervention on the control of LDL-C concentration in patients with ASCVD.

DESIGN, SETTING AND

PARTICIPANTS

This was a pragmatic, 2-arm, cluster randomized clinical trial. A total of 28 clusters (public or private outpatient clinics) in Brazil were randomized to receive a digitally enabled QI intervention or routine practice (control). Adult patients (≥18 years) with established ASCVD were enrolled between November 2023 and December 2024 and followed up for 6 months.

INTERVENTION: The intervention comprised a structured, digitally enabled QI strategy integrating previsit screening, electronic clinical decision support algorithms, audit and feedback mechanisms, and targeted clinician and patient engagement tools embedded within routine workflows to support lipid monitoring, treatment intensification, and adherence.

MAIN OUTCOMES AND MEASURES: The primary outcome was mean LDL-C level at 6 months. Secondary outcomes included relative LDL-C change, achievement of LDL-C targets (<50 mg/dL and ≥50% reduction; to convert to millimoles per liter, multiply by 0.0259), and prescription of lipid-lowering therapies. All analyses were performed following the intention-to-treat principle and accounted for the cluster design by using a generalized estimating equations model.

RESULTS

Among 1465 enrolled patients (mean [SD] age, 62.3 [10.1] years; 894 male [61.0%]; 714 intervention; 751 control), mean (SD) LDL-C concentration at 6 months was 76.3 (37.5) mg/dL in the intervention group and 85.6 (37.1) mg/dL in the control group. The adjusted mean difference was -6.62 mg/dL (95% CI, -11.11 to -2.13 mg/dL; P = .004). Patients in the intervention group were more likely to achieve an LDL-C concentration less than 50 mg/dL (23.5% vs 13.4%; odds ratio, 1.86; 95% CI, 1.30-2.65) and a 50% or greater reduction in LDL-C concentration (18.6% vs 13.4%; odds ratio, 1.76; 95% CI, 1.27-2.43). Prescription of intensive and combination lipid-lowering therapy was significantly higher in the intervention group. No significant differences in major cardiovascular events were observed.

CONCLUSIONS AND RELEVANCE: In this pragmatic cluster randomized clinical trial, a digitally enabled, multifaceted strategy produced modest LDL-C reduction and increased treatment intensification among patients with ASCVD. However, a proportion of patients had LDL-C levels that remained above recommended LDL-C targets, underscoring that the strategy tested was only partially effective in eliminating the residual care gap.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05622929.

Для цитирования: Machline-Carrion M Julia, Santo Karla, Girotto Alysson Nathan, Raupp Priscila, Pereira Pedro Marton, Monfardini Frederico, Nakagawa Santos Renato Hideo, Pereira Mariane, Dos Santos Sampaio Bruna, Moia Diogo, de Oliveira Farias Gabriela, Dall'Orto Frederico Toledo Campo, Pavanello Ricardo, Polanczyk Carisi Anne, Silvestre Odilson Marcos, Assad Marcelo Heitor Vieira, de Oliveira Paiva Maria Sanali Moura, Dos Santos Mayler Olombrada Nunes, Okoshi Marina Politi, Bosso Carlos Eduardo da Costa Nunes, de Azeredo Bastos Leandro Andrade, de Moura Joaquim Rodrigo, Arruda José Airton, Araujo Gustavo Ferreira, Riquena Barbara, Rezende Vania, Alvarenga Lenio, Ray Kausik, Cannon Christopher P, Santos Raul D, Berwanger Otávio, SAPPHIRE-LDL Investigators. Digitally Enabled Quality Improvement Intervention and LDL-C Control in Atherosclerotic Cardiovascular Disease: The SAPPHIRE-LDL Cluster Randomized Clinical Trial.. JAMA cardiology. 2026. DOI: 10.1001/jamacardio.2026.2510.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.